Curated from social media posts and threads
1. Federal Tax Guidance Urgent for Cannabis Businesses
Lawmakers press IRS for immediate guidance on Form 280E tax relief following cannabis Schedule III rescheduling. New tax framework could unlock $billions in deductions for MSOs and cultivators operating under federal approval.
2. Medical Cannabis Gets Federal Green Light
DOJ downgrades medical cannabis classification, enabling legitimate research funding and federal tax benefit claims. Medical cannabis companies now eligible for Section 280E deduction relief and banking partnerships.
Read on News from the States →
3. Vireo Growth’s M&A Blitz Continues
MSO Vireo completes four deals in May, signaling consolidation surge. Buying spree now extends to real estate and agribusiness holdings, making Vireo the largest consolidator in 2026.
4. Vireo Exercises NY Facility Purchase Option
Vireo Growth exercises option to purchase New York cultivation facility from Innovative Industrial Properties. Major expansion move signals confidence in Northeast market growth and MSO footprint consolidation.
5. ACE Ventures Acquires Vireo NY Operations
ACE Venture completes 51% acquisition of Vireo Health New York, launching Bouquet cannabis lifestyle brand. Strategic partnership signals demand for premium cannabis retail experiences in consolidating market.
Read on Business of Cannabis →
6. SNDL Moves Forward on Ontario Stores Acquisition
Sundial Growers announces update on arrangement with 1CM for Ontario Cannabis Stores acquisition. Canadian MSO expands retail footprint in largest cannabis market amid consolidation trends.
7. State-Level Developments Favor Cannabis Investors
Multiple state regulatory initiatives signal investor confidence beyond federal rescheduling. DOJ/DEA recreational hearings expected to accelerate as summer legalization momentum builds.
Read on Cabot Wealth Network →
8. MSO Uplisting Questions Heat Up
Industry debates pros/cons of major MSO uplistings to major exchanges post-rescheduling. Legal analysis suggests pathway clearing for NASDAQ/NYSE listings as federal obstacles diminish.
9. $25B in State Tax Revenue Generated
Legal cannabis has generated $25 billion in cumulative tax revenue for U.S. states—nearly double what alcohol taxes bring in. Market growth trajectory supports bullish investor thesis for 2026-2027.
10. DEA Schedule III Rescheduling Deep Dive
CannIntel covers ongoing implications of Schedule III classification change on banking, research, and business operations. Comprehensive analysis of tax, lending, and research opportunities unlocked.
